文献速递急性肾损伤慢性肾脏病

顺铂诱导慢性肾脏病中的调节性坏死与修复失败

Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease.
PubMed 文献 · Kidney Int · 2019-01-01

本研究在小鼠中比较单次与两次腹腔注射顺铂(间隔2周)后的肾功能与形态学变化,发现两次给药后肾功能未能恢复至基线,多光子显微镜显示肾小球上皮和近端小管损伤加重,但无纤维化、巨噬细胞浸润或内皮细胞减少;微阵列通路分析提示调节性坏死是慢性化的关键因素,Western blot证实坏死性凋亡相关蛋白激活及TLR2/4等上游激活物表达增加。

要点

  • 两次顺铂暴露后肾功能未恢复,提示急性肾损伤向慢性肾脏病转化。
  • 慢性病变肾脏无纤维化、巨噬细胞浸润或内皮细胞减少。
  • 调节性坏死通路持续激活而非纤维化促进CKD进展。

核心结论

  • 未消退的损伤和调节性坏死通路的持续激活,而非纤维化,促进顺铂诱导的急性肾损伤向慢性肾脏病进展。

研究设计与样本

  • 小鼠实验研究:分别给予1次或2次腹腔注射顺铂,两次给药间隔2周,采用功能与形态学指标评估。

主要发现

  • 两次给药组在第二次给药2周后肾功能未恢复正常,而单次给药组在首次给药2周后肾功能接近基线。
  • 多光子显微镜显示两次给药组肾小球上皮和近端小管损伤较单次给药组增加。
  • 慢性病变肾脏无纤维化、巨噬细胞浸润或内皮细胞数量减少的证据。
  • 微阵列通路分析显示调节性坏死是顺铂给药后慢性肾脏病发展的关键决定因素。
  • Western blot显示坏死性凋亡相关蛋白激活,肾损伤标志物、细胞应激反应调节因子及Toll样受体2和4表达增加。

临床怎么用

  • 监测顺铂重复暴露患者的肾功能恢复情况,警惕急性损伤向慢性化转化。
  • 未来可探索靶向调节性坏死通路以阻止顺铂肾毒性慢性进展。

局限性

  • 研究为小鼠模型,结果外推至人类需谨慎。
  • 未明确调节性坏死通路干预能否逆转慢性化进程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cisplatin is an effective chemotherapeutic agent, but significant nephrotoxicity limits its clinical use. Despite extensive investigation of the acute cellular and molecular responses to cisplatin, the mechanisms of progression from acute to chronic kidney injury have not been explored. We used functional and morphological metrics to establish a time-point when the transition from acute and reversible kidney injury to chronic and irreparable kidney disease is clearly established. In mice administered 1 or 2 doses of intraperitoneal cisplatin separated by 2 weeks, kidney function returned toward baseline two weeks after the first dose, but failed to return to normal two weeks following a second dose. Multiphoton microscopy revealed increased glomerular epithelial and proximal tubular damage in kidneys exposed to two doses of cisplatin compared with those exposed to a single dose. In contrast, there was no evidence of fibrosis, macrophage invasion, or decrease in endothelial cell mass in chronically diseased kidneys. Pathway analysis of microarray data revealed regulated necrosis as a key determinant in the development of chronic kidney disease after cisplatin administration. Western blot analysis demonstrated activation of proteins involved in necroptosis and increased expression of kidney injury markers, cellular stress response regulators, and upstream activators of regulated necrosis, including Toll-like receptors 2 and 4. These data suggest that unresolved injury and sustained activation of regulated necrosis pathways, rather than fibrosis, promote the progression of cisplatin-induced acute kidney injury to chronic kidney disease.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Landau SI, Guo X, Velazquez H, et al. Regulated necrosis and failed repair in cisplatin-induced chronic kidney disease. Kidney Int. 2019. PMID: 30904067. doi:10.1016/j.kint.2018.11.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。